/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
Crystal Research Associates has issued an 11-page Quarterly Update on specialty biotech pharmaceutical research and development (R&D) company, FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), detailing the Company's recent news and developments—including its recent permission from the U.S. FDA on June 1, 2020 to submit an Investigational New Drug Application (IND) to use FSD201 to treat COVID-19 (the disease caused by the SARS-CoV-2 virus)—as well as its recent financial position. The report is available for download below.
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS/apple-app-store.png?width=144&name=apple-app-store.png "available on the app store")
/google-play.png?width=130&name=google-play.png "android app on google play")